Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer | Zendy

Matthew D. Galsky | Zendy; Amir Mortazavi | Zendy; Matthew I. Milowsky | Zendy; Saby George | Zendy; Sumati Gupta | Zendy; Mark T. Fleming | Zendy; Long H. Dang | Zendy; Daniel M. Geynisman | Zendy; Radhika Walling | Zendy; Robert Alter | Zendy; Mohamad Kassar | Zendy; Jue Wang | Zendy; Shilpa Gupta | Zendy; Nancy B. Davis | Zendy; Joel Picus | Zendy; George Philips | Zendy; David I. Quinn | Zendy; G. Kenneth Haines | Zendy; Noah M. Hahn | Zendy; Qianqian Zhao | Zendy; Menggang Yu | Zendy; Sumanta K. Pal | Zendy

Open Access

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Author(s) -

Matthew D. Galsky,

Amir Mortazavi,

Matthew I. Milowsky,

Saby George,

Sumati Gupta,

Mark T. Fleming,

Long H. Dang,

Daniel M. Geynisman,

Radhika Walling,

Robert Alter,

Mohamad Kassar,

Jue Wang,

Shilpa Gupta,

Nancy B. Davis,

Joel Picus,

George Philips,

David I. Quinn,

G. Kenneth Haines,

Noah M. Hahn,

Qianqian Zhao,

Menggang Yu,

Sumanta K. Pal

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.03091

Subject(s) - medicine , urothelial cancer , pembrolizumab , chemotherapy , placebo , oncology , metastatic urothelial carcinoma , cancer , randomized controlled trial , double blind , urothelial carcinoma , bladder cancer , immunotherapy , pathology , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research